Schini, M. orcid.org/0000-0003-2204-2095, Gossiel, F., Paggiosi, M.A. orcid.org/0000-0002-1030-0723 et al. (4 more authors) (2025) Randomized controlled trial of an oral gastrin receptor antagonist for the treatment of postmenopausal osteoporosis. Journal of Bone and Mineral Research. zjaf165. ISSN: 0884-0431
Abstract
High gastrin levels may help to explain the association between several conditions and osteoporosis, such as pernicious anemia, the use of proton pump inhibitors, and atrophic gastritis. This study aimed to determine whether administering a gastrin receptor antagonist (GRA) to older women would lower their bone turnover markers (BTM) and, therefore, be a suitable preventive measure for osteoporosis. We conducted a randomized, double-blind, placebo-controlled clinical trial to assess the efficacy, safety, and tolerability of an oral GRA (netazepide) 100 mg administered daily for 90 d in postmenopausal women. Our primary endpoint was the change in the BTM plasma CTX (automated immunoassay analyzer) at days 0, 7, 28, 56, and 90. We also measured other BTMs, and gastrin and group I pepsinogens (ELISA assays). We studied the effect of the drug on the log-transformed baseline scaled ratio for BTM and gastric markers using mixed-model ANOVA for the fixed effects of treatment, time, and the treatment-by-time interaction, with the baseline value included as a covariate. We studied 99 women, with a mean age of 60 yr and bone mineral density (BMD) T-scores for the spine and total hip (TH) of −0.96 and −0.09, respectively. We found that gastrin increased by 90% in response to GRA as early as 7 d (p-value for treatment: .0008), and group I pepsinogens decreased by 15% as early as 7 d (p-value: .0002). There was no significant change in plasma CTX. A high percentage of women (81/99) completed the study, and the GRA was well tolerated. Gastrin receptor antagonist had the expected effects on the gastric markers with an increase in gastrin and a decrease in group I pepsinogens. However, the absence of any change in the bone resorption marker plasma CTX was a bit surprising. Based on this study, it appears that short-term gastrin receptor antagonism is unlikely to be a successful strategy in the prevention of osteoporosis. However, this is a preliminary exploration of a novel hypothesis and larger studies might be needed.
Metadata
| Item Type: | Article |
|---|---|
| Authors/Creators: |
|
| Copyright, Publisher and Additional Information: | © The Author(s) 2025. Published by Oxford University Press on behalf of the American Society for Bone and Mineral Research. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
| Keywords: | osteoporosis; treatment; netazepide; gastrin receptor antagonist; bone turnover markers; clinical trial |
| Dates: |
|
| Institution: | The University of Sheffield |
| Academic Units: | The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Medicine and Population Health |
| Date Deposited: | 10 Dec 2025 15:42 |
| Last Modified: | 10 Dec 2025 15:42 |
| Status: | Published online |
| Publisher: | Oxford University Press (OUP) |
| Refereed: | Yes |
| Identification Number: | 10.1093/jbmr/zjaf165 |
| Related URLs: | |
| Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:235393 |
Download
Filename: zjaf165.pdf
Licence: CC-BY 4.0

CORE (COnnecting REpositories)
CORE (COnnecting REpositories)